A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(19 sites)
United States
MD Anderson Cancer Center, Houston, Texas NEXT Oncology, San Antonio, Texas NEXT Virginia, Fairfax, Virginia China
Anhui Provincial Cancer Hospital, Hefei, Anhui Beijing Cancer Hospital, Beijing, Beijing Municipality The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Hubei Cancer Hospital, Wuhan, Hubei Hunan Cancer Hospital, Changsha, Hunan The First Affiliated Hospital of Nanchang University - Donghu District, Nanchang, Jiang Linyi Cancer Hospital, Linyi, Shandong Shanghai Tenth People's Hospital, Shanghai, Shanghai Municipality West China Hospital, Sichuan University, Chengdu, Sichuan Sir Run Run Shaw Hospital - Zhejiang University School of Med, Hangzhou, Zhejiang The First Affiliated Hospital - Zhejiang University School of Medicine, Hangzhou, Zhejiang The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang
Beijing Cancer Hospital, Beijing, China, Beijing Shanghai Chest Hospital, Shanghai, China, Shanghai Shanghai Zhongshan Hospital, Shanghai, China, Shanghai Interested in joining?